Boumarang S-1/A Filing Reveals $120 Million IPO Target for 22 June
2h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
ipos-1boumarang
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Boumarang Inc. filed an amended Form S-1/A with the U.S. Securities and Exchange Commission on 22 June 2026, detailing its initial public offering plans. The filing, sourced from investing.com, indicates the company intends to raise approximately $120 million by offering 8 million shares at a price range of $14 to $16. The final pricing is scheduled for the date of the filing, 22 June 2026, with trading expected to commence the following day. This event provides the first comprehensive financial disclosure for the consumer goods company seeking a public listing.
The IPO market for mid-cap consumer brands has shown selective receptivity in 2026, contrasting with the broad freeze of 2024-2025. The last comparable IPO in the household products segment was Grove Collaborative's $150 million offering in September 2025, which priced at the low end of its range and traded flat for its first quarter. The current macro backdrop features a Federal Reserve funds rate at 4.75%, creating a higher hurdle for growth-stage companies to justify valuations against risk-free returns. Boumarang's decision to proceed now was likely triggered by a narrowing window before the Q3 earnings season and a need to capitalize on a recent six-month streak of gross margin expansion above 40%, as revealed in the filing.
The S-1/A filing contains several key financial metrics. Boumarang reported $185.2 million in revenue for the fiscal year ending 31 December 2025, a 22% increase from the $151.8 million reported in 2024. The company's net loss narrowed to $12.4 million in 2025, compared to a $28.7 million loss the prior year. Its gross margin improved to 42.1% in 2025, up from 38.5% in 2024. The proposed IPO values the company at an implied market capitalization between $784 million and $896 million at the midpoint of the price range. This valuation represents a forward price-to-sales multiple of approximately 4.2x, based on projected 2026 revenue of $210 million. This compares to a sector average of 3.8x for comparable public peers like The Honest Company (HNST) and Olaplex (OLPX). A key metric shows the company's inventory turnover improved from 4.1x in 2024 to 5.3x in 2025, indicating more efficient operations.
| Metric | FY 2024 | FY 2025 | Change |
|---|---|---|---|
| Revenue | $151.8M | $185.2M | +22% |
| Net Loss | ($28.7M) | ($12.4M) | -56.8% |
| Gross Margin | 38.5% | 42.1% | +360 bps |
The peer comparison shows a divergence. While Boumarang's growth outpaces HNST's 8% revenue growth, its margin profile remains below OLPX's 65% gross margin, reflecting different product cost structures.
The successful pricing of Boumarang's IPO could provide a modest tailwind for other consumer brands contemplating a public listing, particularly those with strong direct-to-consumer channels. Specific tickers that may see positive sentiment include Warby Parker (WRBY) and FIGS (FIGS), as they share similar growth-to-profitability narratives and could benefit from renewed investor appetite for the cohort. Conversely, a failed or poorly received offering would reinforce caution toward the entire segment, potentially pressuring the valuations of recently listed peers. A key counter-argument is that the company's adjusted EBITDA remains negative, at -$4.2 million for 2025, raising questions about the path to sustained profitability amid planned post-IPO marketing expenditures. Early positioning data from the filing indicates that venture capital funds are not selling significant shares in the offering, signaling insider confidence, while the lead underwriters have a 30-day option to purchase up to 1.2 million additional shares to cover over-allotments.
The immediate catalyst is the final pricing confirmation after market close on 22 June 2026. The first day of trading on 23 June will be critical for gauging initial demand; a close above the $16 offer price would signal strong reception. The next major test will be the company's first earnings report as a public entity, expected in late August 2026, where guidance for Q4 will be scrutinized. Technical levels to watch include the $14 price as key support, representing the low end of the filing range, and the $18.50 level, which would represent a 15% gain from the range midpoint and a likely resistance area from early lock-up expiration concerns. Should the Federal Reserve's July meeting signal a more dovish stance, it could improve the environment for growth IPOs like Boumarang later in the year.
An S-1/A is an amended version of the S-1 registration statement filed with the SEC. Companies file amendments to update financial information, respond to SEC comments, or revise offering terms like the number of shares or price range before an IPO becomes effective. The Boumarang filing amends a previously submitted S-1 to include audited full-year 2025 results and set the final offer price range, a mandatory step before shares can be sold to the public.
Boumarang's implied valuation of approximately 4.2x forward sales sits between the valuations of recent successful and challenged IPOs. Reddit (RDDT) priced at nearly 10x sales in 2025, while certain biotech IPOs have priced below 3x. In its specific household products niche, the multiple is slightly above the peer average, justified by its higher growth rate but challenged by its lack of profitability, a balance investors will weigh closely.
If the IPO does not price on the scheduled date, the offering is typically delayed. This can occur if market conditions deteriorate sharply or if investor demand during the roadshow is insufficient to meet the minimum raise target. A delay is often viewed negatively and can lead to a downward revision of the price range or a reduction in the number of shares offered in a subsequent filing, potentially impacting the company's planned use of proceeds for expansion.
Boumarang's amended filing sets a concrete $120 million test for IPO investor appetite in mid-cap growth brands amid elevated interest rates.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.